Efforts to treat COVID-19 with complement targeted treatment strategies have already been explored with various complement inhibitors at both the C3 [20] and C5 [21], refs. [22,23] levels tested as well as C1 inhibitors [24] and MASP-2 [25]. This evidence concerns the gene C5 and COVID-19.